Welcome to our dedicated page for BioRegenx SEC filings (Ticker: BRGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioRegenx, Inc. filings document the company's public-reporting status, annual-report timing and corporate identity, including its former name, Findit, Inc. The Form 12b-25 notification for its Form 10-K records an audit and preparation delay for the annual report period and identifies the registrant's reliance on the SEC late-filing procedure.
BioRegenx, Inc. reported Q1 2026 net sales of $426,175, down 17% from $515,147 a year earlier as medical testing machine issues weighed on product demand. Gross profit was $348,288, with cost of sales falling 29%, but lower volumes still reduced gross profit versus Q1 2025.
Operating expenses declined sharply to $398,052 from $598,646, driven by reduced equity compensation, legal, accounting and professional fees. The company also recorded $100,435 of other income, largely from a write-off of accrued liabilities, partially offset by $77,086 of interest and financing costs.
Net loss narrowed to $26,415 from $266,854. Despite this improvement, BioRegenx ended the quarter with cash of $45,806, a stockholders’ deficit of $4,533,316, total liabilities of $4,870,386, and notes in default with aggregate principal of $522,500, leading management and auditors to conclude there is substantial doubt about its ability to continue as a going concern.
BioRegenx, Inc. develops medical test equipment, AI-driven telehealth technologies and science-based nutritional products sold to healthcare professionals and consumers. In 2025, net sales were $1.85 million, down from $2.34 million in 2024, mainly due to product issues with its medical testing platform that reduced distributor activity.
The company reported a 2025 net loss of $1.54 million, a sharp improvement from a $23.05 million loss in 2024, largely because 2024 included heavy impairment and amortization charges. Despite this, BioRegenx ended 2025 with stockholders’ deficit of $4.54 million, cash of $69,383, and notes payable of about $1.19 million plus $1.03 million of related-party loans, with $522,500 of notes in default.
Management and the auditors state there is substantial doubt about the company’s ability to continue as a going concern, given recurring losses, negative equity, limited liquidity and debt defaults. Operations span microvascular health products, AI-based remote diagnostics through DocSun, wellness supplements via MyBodyRx and NuLife, and the Findit AI Connect digital marketing platform.
BioRegenx, Inc. reported Q3 results showing smaller losses and lean liquidity. Net sales were $507,755 versus $596,037 a year ago, with gross profit of $426,397. Operating expenses declined sharply due to the absence of prior-year amortization, narrowing loss from operations to $8,459 from $327,307. Net loss was $80,565 versus $394,860 in the prior-year quarter.
For the nine months, net sales were $1,468,872 versus $1,879,617, and net loss was $525,764 versus $4,653,446. Cash was $46,947 and stockholders’ deficit was $3,647,136 as of September 30, 2025. Management disclosed “substantial doubt” about the company’s ability to continue as a going concern, noting $522,500 of notes in default and EIDL delinquencies of $400,000, both classified as current. Total liabilities were $4,814,900.
The company recorded a GlycoCheck sublicense with a three-year minimum royalty of $750,000, recognizing an intangible asset of $725,000 (net) and a $700,000 royalty liability. Common shares outstanding were 961,992,601 as of November 9, 2025.